Clinical Trial of Targeted Alpha Therapy for Prostate Cancer

Prostate Cancer Clinical Trial

— Alpha-PS1  

Official title:

A Phase I Investigator-initiated Clinical Trial of a Novel Targeted Alpha Therapy for Patients With Castration-resistant Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06441994
• Other study ID #: APS1-001
• Status: Recruiting
• Phase: Phase 1
• Start date: May 24, 2024
• Est. completion date: March 31, 2027

Study information

• Verified date: June 2024
• Source: Osaka University
• Contact: Tadashi Watabe, M.D., Ph.D.
• Phone: +81-6-6879-3434
• Email: watabe.tadashi.med[@]osaka-u.ac.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.

Description:

PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II. PSW-1025 (At-211 PSMA-5) is an alpha-ray-emitting drug labeled with Astatine (At-211) that targets PSMA (Prostate Specific Membrane Antigen).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: March 31, 2027
• Est. primary completion date: March 31, 2027
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with progressive castration-resistant prostate cancer who meet the following conditions (1) and (2) (1) Patients with progressive increase of serum Prostate-Specific Antigen (PSA) (>=2ng/mL, three consecutive increases at least one week apart, and two increases of more than 50% from the lowest value), or with the tumor growth or appearance of new lesions detected by imaging studies (2) Patients with the serum testosterone at castration level (< 50ng/dL)

2. Patients who meet the following conditions (1) and (2), resistant to standard treatment or not indicated for the generally approved standard treatments (1) Patients who have received at least one of the following treatments

• Inhibitors of androgen receptor signaling (enzalutamide, apalutamide, dalortamide, etc.)

• Inhibitors of Cytochrome P450 17 (CYP 17) (abiraterone acetate) (2) Patients previously treated with the taxane-based chemotherapy (docetaxel or cabazitaxel) or not adapted for the taxane-based chemotherapy (including refusal cases)* * Targeting for the patients who have received cabazitaxel therapy after docetaxel therapy, or patients for whom cabazitaxel therapy was not indicated (including refusal cases) after docetaxel therapy, or patients for whom both docetaxel therapy and cabazitaxel therapy were not indicated (including refusal cases)

3. Patients aged 18 years or older at the time of consent acquisition

4. Patients with stable general condition with PS (Performance status) of 0 to 2 in ECOG (Eastern Cooperative Oncology Group)

5. Patients who can be expected to survive for 6 months or more, judging from clinical symptoms and medical examination findings

6. Patients without or with controlled symptomatic brain metastases

7. Patients with no clinically significant abnormal findings in electrocardiogram, respiratory rate, and blood oxygen saturation within 30 days before the enrollment

8. Patients whose laboratory values within 30 days before the enrollment are within the range specified in the protocol

9. Patients who can use appropriate contraception during the clinical trial period according to the protocol

10. Patients who thoroughly listened to the explanation of the clinical trial, agreed to the various study procedures outlined in the clinical trial protocol and signed the consent document

Exclusion Criteria:

1. Patients who received systemic antitumor therapy (e.g. chemotherapy, immunotherapy, biologic therapy such as monoclonal antibodies, excluding androgen receptor signaling inhibitors) within 4 weeks before enrollment

2. Patients who received radium chloride (Radium, 223Ra) or 177Lu (Lutetium)-PSMA-617 within 6 months before registration

3. Patients currently receiving treatment with other cytotoxic chemotherapy, immunotherapy, radioligand therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, AKT inhibitors

4. Patients with active double cancer (simultaneous double cancer and ectopic double cancer with a disease-free period of 5 years or less)

5. Patients who received other investigational drugs within 5 weeks prior to enrollment

6. Patients with uncontrollable active infections

7. Hepatitis B surface antigen positive, Hepatitis C Virus antibody positive (patients with HCV-RNA level below the limit of detection can be registered) or Human Immunodeficiency Virus antibody positive patients

8. Patients with mental illness or psychiatric symptoms who are judged to be difficult to participate in clinical trials

9. Other patients who are judged to be inappropriate by the investigator, etc.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• PSW-1025
PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)

Locations

Country	Name	City	State
Japan	Osaka University Hospital	Suita	Osaka

Sponsors (2)

Lead Sponsor	Collaborator
Osaka University	Japan Agency for Medical Research and Development

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-related adverse events as assessed by CTCAE v5.0		until 6 months after administration
Primary	Dose Limiting Toxicity		within 4 weeks after single administration
Secondary	Number of participants with adverse events and their details		until 6 months after administration
Secondary	Blood pressure (mmHg) and heart rate (bpm)		until 6 months after administration
Secondary	Symptoms of the participants		until 6 months after administration
Secondary	Hematological tests (blood cell counts)		until 6 months after administration
Secondary	Urine tests (occult blood and urine protein)		until 6 months after administration
Secondary	Electrocorticogram		until 6 months after administration
Secondary	Prostate-Specific Antigen (PSA) (ng/ml)		until 6 months after administration
Secondary	Tumor size on CT (mm)		until 6 months after administration
Secondary	Excretion rates in urine, feces, and breath (%injected dose)		until 24 hours after administration
Secondary	Absorbed doses in major organs (Gy)		until 24 hours after administration